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Abstract
Huntington’s disease (HD) is a devastating neurodegenerative disorder for which there are no disease-modifying
treatments. The molecular pathogenesis of HD is complex and many mechanisms and cellular processes have been
proposed as potential sites of therapeutic intervention. However, prior to embarking on drug development initiatives, it is
essential that therapeutic targets can be validated in mammalian models of HD. Previous studies in invertebrate and cell
culture HD models have suggested that inhibition of SIRT2 could have beneficial consequences on disease progression.
SIRT2 is a NAD
+-dependent deacetylase that has been proposed to deacetylate a-tubulin, histone H4 K16 and to regulate
cholesterol biogenesis – a pathway which is dysregulated in HD patients and HD mouse models. We have utilized mice in
which SIRT2 has been reduced or ablated to further explore the function of SIRT2 and to assess whether SIRT2 loss has a
beneficial impact on disease progression in the R6/2 mouse model of HD. Surprisingly we found that reduction or loss of
SIRT2 had no effect on the acetylation of a-tubulin or H4K16 or on cholesterol biosynthesis in the brains of wild type mice.
Equally, genetic reduction or ablation of SIRT2 had no effect on HD progression as assessed by a battery of physiological
and behavioural tests. Furthermore, we observed no change in aggregate load or levels of soluble mutant huntingtin
transprotein. Intriguingly, neither the constitutive genetic loss nor acute pharmacological inhibition of SIRT2 affected the
expression of cholesterol biosynthesis enzymes in the context of HD. Therefore, we conclude that SIRT2 inhibition does not
modify disease progression in the R6/2 mouse model of HD and SIRT2 inhibition should not be prioritised as a therapeutic
option for HD.
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Introduction
Huntington’s Disease (HD) is a devastating, autosomal domi-
nant, neurodegenerative disorder, with a mean age of onset of 40
years [1]. HD symptoms are typically movement disorders, rapid
weight loss, dementia and psychiatric disturbances, and the disease
progresses to death over the course of 15–20 years [1–3]. The
progressive atrophy of the cerebral cortex and basal ganglia is the
most striking neuropathological change, although other brain
regions are also affected with the result that HD patients can lose
as much as 40% of their brain volume [4–6]. At the molecular
level HD is caused by the expansion of a CAG tri-nucleotide
repeat within exon 1 of the huntingtin gene (HTT), which
translates into an expanded polyglutamine (polyQ) tract in the N-
terminus of the huntingtin protein (HTT) [7]. Ubiquitin positive
cytoplasmic aggregates and intranuclear inclusions which appear
to consist of N-terminal mutant HTT (mHTT) fragments [8], are
a prominent neuropathological feature. Disturbances in many
cellular processes including transcriptional regulation, synaptic
function, intracellular trafficking and energy homeostasis have
been observed in HD [9]. Whether these contribute to or are an
effect of HD pathology is currently unclear [9]. Therapeutic
options currently available to HD patients are directed against
primary symptoms such as chorea or depression, however, these
approaches do not modify disease progression and as such, have
limited benefits [3].
Histone deacetylase (HDAC) inhibition has recently emerged as
an attractive therapeutic intervention for many complex diseases,
including HD. There are altogether 18 mammalian HDACs,
divided into four classes depending on their sequence homology to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34805yeast enzymes. HDACs 1 through 11 are all zinc dependent
enzymes, share the same reaction mechanism and belong to classes
I, II and IV [10]. Sirtuins form the class III deacetylases which
contain seven enzymes that are similar to the yeast Sir2, thus
named SIRT1 through SIRT7 [11]. The sirtuin reaction
mechanism is NAD
+ (nicotinamide adenine dinucleotide) depen-
dent and proceeds through the formation of an oxocarbenium-like
transition species and the release of nicotinamide (NAM) [12]. As a
side product of the deacetylation reaction, NAM is a pan-sirtuin
inhibitor. Treatment with NAM has shown beneficial effects in a
mouse model of HD [13]. However, it has also been demonstrated
that depletion of SIRT1 exacerbates phenotypes in an HD mouse
model [14]. Therefore, pan-inhibition of all sirtuins could have a
less positive net effect than the inhibition of a specific sirtuin other
than SIRT1. It is thus important to identify which sirtuin(s), when
inhibited, has beneficial consequences for HD.
SIRT2 is the only member of the sirtuin family residing
primarily in the cytoplasm, where it has been shown to deacetylate
a-tubulin [15,16]. Other clients of SIRT2 include histone 4
acetylated at lysine 16 (H4K16), FOXO1, FOXO3a, p53 and
PEPCK1, and it has therefore been suggested that SIRT2 has a
role in cell cycle progression and the regulation of gluconeogenesis
as well as the stress responses to caloric restriction and cold
exposure [17–21].
Evidence for a protective role of SIRT2 inhibition in HD came
from two important studies. Firstly, genetic knock-down of Sirt2 to
50% of normal levels prevented photoreceptor neuron degener-
ation in a HTT exon 1 D. melanogaster HD model, but did not
rescue lethality [22]. In a second study, a specific SIRT2 inhibitor
was demonstrated to be protective in D. melanogaster, C. elegans and
primary striatal cell models of HD [23]. Although microarray
profiling of HD striatal cells showed that SIRT2 inhibition did not
correct the transcriptional dysregulation associated with HD, it
revealed an unanticipated function for SIRT2 in cholesterol
biosynthesis. Treatment of striatal cells with the SIRT2 inhibitor
AK-1 resulted in a down-regulation of key enzymes in the
cholesterol synthesis pathway. Further examination revealed that
SIRT2 facilitates the nuclear translocation of SREBP-2 and
subsequent activation of the cholesterol synthesis pathway.
Consistent with this, inhibition of SIRT2 decreased nuclear
SREBP-2, and consequently the expression levels of the
cholesterogenic enzymes and therefore levels of cholesterol. It
was proposed that the neuroprotective effect observed after
treatment with SIRT2 inhibitors was due to a reduction in the
high cholesterol levels observed in the HD striatal cells that had
been used [23]. These findings strongly suggested that SIRT2
inhibition should modify HD progression.
Based on previous studies in worm, fly and cell culture HD
models, we might expect that loss of SIRT2 would decrease
aggregate load and cholesterol levels and modify HD progression
in a mouse model of HD [22,23]. To verify whether this is the
case, Sirt2 knock-out (Sirt2KO) mice have been crossed to the R6/
2 mouse model of HD and disease progression was assessed with
physiological, behavioural and molecular readouts. The R6/2
mouse has an early onset and rapid phenotype progression and at
late stage disease expresses HD-related phenotypes that are
extremely similar to those that develop in the genetically precise
HdhQ150 knock-in HD model [24–29]. Here we show that genetic
depletion of SIRT2 does not affect disease progression in R6/2
mice. Additionally, we have observed no difference in the levels of
soluble or aggregated mHTT transprotein upon SIRT2 ablation.
Finally, we were unable to detect a role for SIRT2 in the
cholesterol synthesis pathway, either in Sirt2KO mice or in mice
acutely dosed with a SIRT2 inhibitor. We find no evidence for the
therapeutic potential of SIRT2 modulation in a mammalian
model of HD and suggest that SIRT2 inhibition should not be
prioritised as a therapeutic strategy for HD.
Results
Sirt2 knock-out mice do not express the SIRT2 protein
Sirt2 knock-out (Sirt2KO) mice were generated by the targeted
insertion of a puromycin resistance gene into exon 11 of the Sirt2
locus. The insertion was sequenced and BLAST analysis
confirmed that in addition to vector backbone sequences, the
mutation introduced a puromycin resistance gene countersense to
the Sirt2 gene (Fig. 1A). Further analysis showed that the insertion
introduces a stop codon that should result in nonsense-mediated
decay of the Sirt2 mRNA (Fig. S1).
To investigate the effects of the mutation on Sirt2 expression,
cortical Sirt2 mRNA levels were measured by quantitative real-
time PCR (qPCR) with primers binding upstream of the insertion
in Sirt2KO, Sirt2HET (Sirt2 heterozygous) and wild type (WT)
mice at 4 weeks of age. Sirt2HET and Sirt2KO mice were found to
express 80% and 60% of Sirt2 mRNA levels as compared to WT
respectively (Fig. 1B). To investigate the mechanism by which the
insertion affects SIRT2 protein synthesis, we probed brain lysates
from 4 week old mice with N- (Santa Cruz H-95) or C-terminal
(Sigma S8447) anti-SIRT2 antibodies. Western blotting revealed 3
bands that correspond to the predicted molecular weight of the
three SIRT2 isoforms (43, 37 and 34 kDa) [30], all of which were
absent in Sirt2KO mice and reduced to 55% of WT levels in
Sirt2HETs (Fig. 1C). These experiments also ruled out the
possibility that the disruption of the Sirt2 gene resulted in the
production of an N-terminal fragment of SIRT2 (Fig. 1D). Finally,
the primarily cytoplasmic localisation of SIRT2 [15,16] was not
modulated by the reduction in SIRT2 levels (Fig. 1E). We have
also ascertained that the reduction or depletion of SIRT2 does not
affect the mRNA expression of the other Hdacs or sirtuins, or the
expression of the SIRT1 protein, which shares the most sequence
homology and substrate specificity with SIRT2 [20,21,31,32] (Fig.
S2).
Genetic depletion of SIRT2 does not affect the
acetylation of tubulin or of H4K16 and does not modify
the expression of the cholesterol biosynthesis enzymes
The first two SIRT2 deacetylation substrates to be proposed
were lysine (K) 40 of a-tubulin and K16 of histone 4 (H4) [15,17].
We have previously shown that knock-out of another tubulin
deacetylase, HDAC6, causes tubulin hyperacetylation throughout
the brain [33]. To verify whether a similar effect would be
observed after SIRT2 genetic depletion, western blotting was
performed on cortical, striatal and cerebellar samples obtained
from 4 week old WT, Sirt2HET and Sirt2KO mice. Interestingly,
tubulin acetylation was not modified by SIRT2 depletion,
indicating that HDAC6, not SIRT2, is the major tubulin
deacetylase in the brain (Fig. 2A–B). To assess the effect of
SIRT2 ablation on the levels of H4K16 acetylation, histones were
enriched by acid extraction from the cortices and livers of 4 week
old mice. Genotype specific differences could not be detected in
the levels of acetylated H4K16 in the tissues examined (Fig. 2C).
Previous studies using mRNA microarray analysis suggested
that inhibition of SIRT2 results in a decrease in the expression of
enzymes that take part in cholesterol synthesis [23]. To verify
whether genetic depletion of SIRT2 has an effect on cholesterol
biosynthesis in the context of a mouse brain, we measured the
expression of seven genes coding for cholesterogenic enzymes,
chosen for analysis on the basis of previously published data [23].
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modified by SIRT2 reduction or ablation in the cortex at 4 weeks
of age (Fig. 2D). This effect was not masked by focusing on a
specific time point, brain region or tissue type as no difference
between WT, Sirt2HET and Sirt2KO mice could be detected in
cortices from 9 week old mice, or brain stem and liver from mice
at 4 weeks of age (Fig. 2E–G). SIRT2 had been proposed to
modulate the expression of cholesterogenic enzymes by increasing
the nuclear localisation of the 60 kDa active form of the
transcription factor SREBP-2, the master regulator of the
Figure 1. Reduction of Sirt2 mRNA and an absence of the SIRT2 protein in Sirt2 knock-out mice. (A) Exon-intron structure of the Sirt2
gene in mouse and the location of the insertion (light blue) in exon 11 (after nucleotide 18883) in Sirt2KO mice. The positions of the sequencing
forward and reverse primers are shown. 1-Sirt2 forward, 2-Sirt2 forward Seq2, 3-Sirt2 forward Seq3, A-Sirt2 reverse KO, B-Sirt2 reverse WT. (B) Cortical
Sirt2 mRNA levels in 4 week old Sirt2KO (KO), Sirt2HET (HET) and wild type (WT) mice. Expression levels were normalised to the housekeeping genes
Atp5b and Canx and expressed as fold change of WT levels 6SEM. n=8/genotype. (C) Western blotting of KO, HET and WT brain lysates with
SantaCruz H-95 (upper panel) and Sigma S8447 (lower panel) antibodies. The S8447 probed blot was used to quantify SIRT2 levels (both bands)
between HET and WT (right panel). Values were normalised to a-tubulin (Tub) and expressed as fold change of WT 6SEM. * denotes a non-specific
band. (D) Western blotting of KO, HET and WT brain lysates with SantaCruz H-95 antibody (long exposure) demonstrating that the Sirt2 disrupting
mutation does not result in the production of an N-terminal fragment of SIRT2. *denotes non-specific bands. (E) SIRT2 is localised to the cytoplasm.
Purity of fractions was determined by measuring the expression of actin (C-cytoplasm) and H3 (N-nucleus).
doi:10.1371/journal.pone.0034805.g001
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able to detect any genotype dependent changes in the intensity of
bands detected with an antibody that recognises both the active
and inactive forms of SREBP-2 (Fig. 2H). Taken together, these
data suggest that the cholesterol biosynthesis pathway is unaltered
in the brains of Sirt2KO mice.
SIRT2 genetic ablation does not improve phenotypes in
the R6/2 mouse model of HD
The potential therapeutic nature of SIRT2 inhibition in HD has
not yet been tested in a complex mammalian system. To address
this, the targeted Sirt2 gene was crossed into the R6/2 mouse
model of HD. The progeny, consisting of WT (n=18), Sirt2HET
(WT HET) (n=21), Sirt2KO (WT KO) (n=16), R6/2 (n=18),
Sirt2HETxR6/2 (R6/2 HET) (n=19) and Sirt2KOxR6/2 (R6/2
KO) (n=15) mice were monitored in a phenotyping study from 4
to 14 weeks of age and sacrificed at 15 weeks of age. The
expression pattern of SIRT2 throughout the brain was consistent
across this time frame (Fig. S3A). Equally, expression of Sirt2
mRNA was not affected by the progression of HD-phenotypes in
R6/2 mice (Fig. S3B). As the CAG repeat size is intimately linked
to age of onset and mHTT toxicity [34], we have ascertained that
mice were well matched for the CAG repeat number across the
genotypes (R6/2 CAG=213, R6/2 HET=214, R6/2
KO=2126 standard deviation of 4 CAG’s for each group).
Mice were weighed weekly from 4 until 14 weeks of age. R6/2
mice weighed significantly less than WT mice overall
(F(1,96)=10.655, p=0.002) and gained weight at a significantly
slower rate (F(3,282)=61.278, p,0.0005). Interestingly, Sirt2HET
and Sirt2KO mice had significantly increased weight
(F(2,96)=4.668, p=0.012) (Fig. 3A–B), starting at 7 weeks of age
(F(2,96)=3.152, p=0.047). This phenomenon showed a trend to
become significant with time (F(6,282)=2.131, p=0.051). However,
the Sirt2 mutation had no overall effect on R6/2 weight loss
(F(2,96)=0.087, p=0.917) or on the decrease in weight of R6/2
mice over time (F(6,282)=1.902, p=0.082), suggesting that if the
Sirt2 mutation modifies weight, it does so independently of HD
progression.
Grip strength was measured in mice at 4 weeks of age and bi-
weekly from 7 to 13 weeks of age. R6/2 mice had reduced grip
strength compared to WT mice (F(1,96)=66.79, p,0.0005). This
deficit appeared by 11 weeks of age (F(1,96)=54.462, p,0.0005)
and deteriorated over time (F(3,308)=78.857, p,0.0005) (Fig. 3C–
D). Grip strength was not altered in mice where SIRT2 was either
reduced (Sirt2HET) or absent (Sirt2KO) overall (F(2,96)=0.654,
p=0.522) or with time (F(6,308)=0.355, p=0.916) and there was
no significant effect of the modulation of SIRT2 levels on the grip
strength deterioration observed in R6/2 mice either overall
(F(2,96)=0.116, p=0.891), or with time (F(6,308)=0.9, p=0.5)
(Fig. 3C–D). These findings strongly suggest that reducing or
ablating SIRT2 does not affect the grip strength in R6/2 mice.
Rotarod performance is a robust measure of motor coordina-
tion and was assessed at 4 weeks of age and bi-weekly from 8 to
14 weeks (Fig. 3E). In line with previous observations, R6/2
mice were indistinguishable from their WT littermates at 4 weeks
of age (F(1,95)=2.128, p=0.148) [35], but their performance
deteriorated over time (F(3,237)=23.792, p,0.0005) (Fig. 3E).
Sirt2HET and Sirt2KO mice did not perform differently from
WT mice overall (F(2,95)=0.23, p=0.795) or with time (F(5,237)=
1.118, p=0.351) and down-regulation or ablation of SIRT2 had
no effect on the rotarod performance of R6/2 mice (F(2,95)=0.634,
p=532) or its deterioration over time (F(5,237)=0.376, p=0.865)
(Fig. 3E). Therefore, it was concluded that neither SIRT2
reduction nor depletion affect rotarod performance in WT or
R6/2 mice.
As expected, R6/2 brains weighed significantly less than those
of WT mice (F(1,41)=17.197, p,0.0005 at 9 weeks and
F(1,96)=268.291, p,0.0005 at 15 weeks of age) (Fig. 3F). Genetic
modulation of Sirt2 had no effect on brain weight in WT or R6/2
mice (F(2,41)=0.734, p=0.486 at 9 weeks and F(2,96)=1.107,
p=0.335 at 15 weeks).
Spontaneous motor activity was measured bi-weekly from 5 to
13 weeks of age. Data were analysed with General Linear Model
repeated measures ANOVA and p-values are presented in Table
S1. Figures S4 and S5 depict 5 min moving averages for activity
and mobility (Fig. S4), and rearing and centre rearing (Fig. S5).
Deficits in mobility were already apparent in R6/2 mice at 5
weeks of age, which is consistent with previous reports [36].
However, the reduction or ablation of SIRT2 had no effect on any
of the parameters at any age tested, did not modify the pattern of
exploration over time and did not affect the hypoactivity of R6/2
mice (Table S1 Sirt2KO Genotype, Time*Sirt2KO, R6/
2*Sirt2KO). These data imply that depletion of SIRT2 has no
effect on the progressive hypoactivity of R6/2 mice.
SIRT2 knock-down and knock-out do not affect
aggregate load or levels of soluble mHTT in R6/2 mice
Although the genetic ablation of SIRT2 had no discernible
disease modifying effect on HD related behavioural and
physiological phenotypes in R6/2 mice, it remained possible that
SIRT2 depletion elicited molecular changes. Mutant HTT
aggregates are formed in HD patients and all known mouse
models and correlate with disease progression [37,38]. To
investigate whether SIRT2 genetic depletion modified levels of
soluble or aggregated mHTT, Seprion ELISA, time resolved –
Fo ¨rster resonance energy transfer (TR-FRET) and Mesoscale
Discovery (MSD) were performed on the cortex, hippocampus,
brain stem and cerebellum from 4, 9 and 15 week old R6/2, R6/2
HET and R6/2 KO mice.
As has been observed previously, the aggregate load in R6/2
mice was highest in the cortex and hippocampus and much lower
in the brain stem (Fig. 4E–G) [26]. As expected, levels of
aggregated mHTT increased and soluble mHTT decreased
Figure 2. SIRT2 depletion does not affect a-tubulin or H4K16 acetylation or the expression of cholesterogenic enzymes. (A)
Representative western blots of acetylated tubulin (Ac-Tub) at 4 weeks of age in the cortex, striatum and cerebellum of WT, Sirt2HET and Sirt2KO
(upper panel) and WT and Hdac6KO (H6KO) mice (lower panel). (B) Quantification of acetylated tubulin in WT, Sirt2HET and Sirt2KO mice. Signal was
normalised to the level of total tubulin (Tub) and expressed as fold change of WT 6 SEM. n=4/genotype. (C) Representative western blots of
acetylated H4K16 (H4K16-Ac) and total H4 (H4) at 4 weeks of age in the cortex and liver of WT, HET and KO mice. n=3/genotype (cortex) and n=6/
genotype (liver). (D–G) The mRNA expression levels of 7 cholesterogenic enzymes were determined by Taqman qPCR in the cortex at (D) 4 and (E)9
weeks of age and in the (F) brain stem and (G) liver at 4 weeks of age between wild type (WT), Sirt2HET (HET) and Sirt2KO (KO) mice. n$6/genotype.
Expression was normalised to the housekeeping genes Atp5b (4 and 9 wk cortex and brain stem), Canx (4 and 9 week cortex and liver), Gapdh (brain
stem and liver), and ActB (liver) and expressed as fold change of WT 6 SEM. (E) Representative immunoblot for SREBP-2 in whole brains of 4 week old
WT, HET, KO mice, performed on the same lysates as in Fig. 1D. The active form of SREBP-2 was expected to migrate at 60 kDa in the nuclear (N)
fractions, the precursor of SREBP-2 was expected to migrate at 120 kDa in the cytoplasmic (C) fractions. n=4/genotype.
doi:10.1371/journal.pone.0034805.g002
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Interestingly, the rate at which levels of soluble mHTT decrease
with disease progression varied greatly between dif-
ferent brain regions (Fig. 4A–D). The Seprion ELISA did not
detect any changes in the aggregate load and TR-FRET did
not detect any changes in the levels of soluble mHTT in the
cortex, hippocampus or brain stem at 4, 9 or 15 weeks of age
between R6/2, R6/2 HET or R6/2 KO mice (Fig. 4). These
results were confirmed by western blotting with an anti-HTT
antibody (S829) (Fig. 5).
The results obtained from the Seprion ELISA and TR-FRET
experiments were confirmed by an MSD assay (Fig. S6).
Importantly, the profiles obtained for the decrease in soluble
mHTT for each brain region were very similar to those seen by
TR-FRET, indicating a high degree of comparability between the
two methods. Although some significant differences were observed
Figure 3. Behavioural and physiological phenotypes elicited by Sirt2 knock-down and knock-out in R6/2 mice. (A–B) Mean body
weight measurements in (A) female and (B) male mice. (C–D) Grip strength in (C) female and (D) male mice. (E) Rotarod performance. (F) Brain weight
measured at 9 and 15 weeks of age. Error bars represent SEM. WT – wild type, HET – Sirt2HET, KO – Sirt2KO, R6/2 HET – Sirt2HETxR6/2, R6/2 KO –
Sirt2KOxR6/2.
doi:10.1371/journal.pone.0034805.g003
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FRET or the Seprion ELISA. Given that the TR-FRET and MSD
assays had been performed on the same lysates, it is more likely
that statistically significant values were obtained by chance as a
result of the large number of comparisons performed rather than
reflecting a biological effect. Taken together, these data demon-
Figure 4. Aggregated and soluble mHTT in the brain at 4, 9 and 15 weeks of age. Levels of soluble mHTT as measured by TR-FRET with
2B7-MW1 antibodies in the (A) cortex, (B) hippocampus (C) brain stem and (D) cerebellum at 4, 9 and 15 weeks of age in R6/2, Sirt2HETxR6/2 (R6/2
HET) and Sirt2KOxR6/2 (R6/2 KO) mice. The signal for each tissue was expressed as fold change of R6/2 at 4 weeks. Signals above background were
not observed for mice without the R6/2 transgene. n$4/genotype/tissue/time point (except for R6/2 KO at 4 weeks where n=3). Error bars represent
SEM. (E–G) Aggregate load in the cortex, hippocampus and brain stem at (E) 4, (F) 9 and (G) 15 weeks of age as measured by Seprion ELISA with the
MW8 antibody. The average signal for WT, HET and KO values was subtracted from each reading and expressed as fold change of R6/2 cortex 6 SEM.
n=6/genotype(R6/2, R6/2 HET and R6/2 KO) or n=3/genotype (WT, HET, KO).
doi:10.1371/journal.pone.0034805.g004
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of mHTT aggregation between 4 and 15 weeks of age in brain
tissues from R6/2 mice.
Cholesterogenic enzyme dys-homeostasis is not
corrected by the genetic depletion of SIRT2
SIRT2 genetic ablation had no effect on the expression of
cholesterogenic enzymes in WT mice (Fig. 2D–G). However, it
was possible that the effects of SIRT2 depletion would only be
apparent in the context of HD pathogenesis. To verify whether
this was the case, we measured the expression of cholesterogenic
enzymes in WT, HET, KO, R6/2, R6/2 HET and R6/2 KO
mice at 15 weeks of age. The R6/2 genotype had a statistically
significant effect on the expression of all cholesterogenic enzymes
(two-way ANOVA) (Fig. 6). The Sirt2 genotype alone had no
significant effect on the expression of any of the cholesterogenic
enzymes. Surprisingly, however, the Sirt2 genotype significantly
modified the effect of the R6/2 genotype on the expression of
Hmgcr (F(2,33)=6.03, p=0.006), Dhcr7 (F(2,36)=5.14, p=0.011)
and Sqle (F(2,36)=3.38, p=0.045). Close inspection of the data
revealed that the statistical significance arises from a SIRT2-
Figure 5. Levels of soluble mHTT in various brain regions at 4, 9 and 15 weeks of age. Representative western blots from cortex,
hippocampus and brain stem of (A–B)4 ,( C–D) 9 and (E–F) 15 week old wild type (WT), Sirt2HET (HET), Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 HET)
and Sirt2KOxR6/2 (R6/2 KO) mice probed with an anti-HTT antibody (S829) and tubulin (Tub) as loading control. Both soluble mHTT transprotein and
aggregates retained in the stacking gel can only be detected in mice expressing the R6/2 transgene (A, C, E). All samples were run on the same gel.
White lines indicate where lanes are not contiguous.
doi:10.1371/journal.pone.0034805.g005
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which would be inconsistent with the proposed biological
mechanism. All of the tested cholesterogenic enzymes are targets
of SREBP-2, therefore, if SIRT2 ablation was causing a decrease
in the nuclear shift of SREBP-2, KO mice should display lowered
expression for all seven enzymes in both R6/2 and WT mice. As
this was not the case, the observed statistical differences are more
likely a result of biological variability than a consequence of
SIRT2 depletion.
Acute inhibition of SIRT2 has no effect on the levels of
cholesterol biosynthesis enzymes in WT or R6/2 mice
The lack of an effect of SIRT2 knock-out on tubulin and
H4K16 acetylation, and on cholesterogenic enzyme expression
could be due to compensatory mechanisms. To investigate
whether this is the case, WT and R6/2 mice at 12 weeks of age
were given a single low (1 mg/kg) or high (3 mg/kg) dose of the
dual SIRT1/SIRT2 inhibitor, [S]-35 [39] (Fig. 7A) by oral
gavage, and tissues were harvested at either 4 or 8 h post dosing.
[S]-35 penetrates the blood brain barrier with brain levels peaking
at 2 h post dosing (Fig. S7). The IC50 for SIRT2 inhibition, as
measured at Cerep (assay 2582) is 560 nM and [S]-35 was found
to inhibit SIRT1 with a similar IC50 (assay 2581). LC/MS/MS
analysis of brain tissue from mice dosed with [S]-35 revealed that
at 4 h post dosing, [S]-35 was still present in both WT and R6/2
mice at concentrations above the SIRT2 IC50 (Fig. 7B).
In line with previous reports and data from this study,
expression of all cholesterogenic enzymes was diminished in R6/
2 vehicle treated mice as compared to WT vehicle treated mice
(Fig. 7C–D) [40]. However, neither dose of [S]-35 affected the
expression of cholesterogenic enzymes at 4 or 8 h post dosing in
either WT or R6/2 mice. These data strongly suggest that SIRT2
inhibition does not modulate the expression levels of cholesterol
biosynthesis enzymes in vivo.
Discussion
Previous studies in invertebrate and cell culture models of HD
have indicated that SIRT2 inhibition alters HD-related pheno-
types, particularly by modulating the expression of cholesterol
biosynthesis enzymes [22,23]. To verify whether these findings
could be translated to a mouse model, we investigated the effects of
SIRT2 genetic reduction and depletion on HD physiological,
behavioural and molecular phenotypes in the R6/2 mouse. The
data presented here show that a reduction in SIRT2 protein levels
to approximately 50% or total ablation of the SIRT2 protein has
no effect on the levels of acetylated tubulin, acetylated H4K16 or
on the expression of enzymes involved in cholesterol biosynthesis.
Additionally, we demonstrate that compensatory mechanisms
have not occurred to maintain the mRNA levels of cholesterogenic
enzymes as no changes in expression were observed after the acute
inhibition of SIRT2. Finally, we show that the reduction or
removal of the SIRT2 protein has no effect on HD progression,
aggregate load or levels of soluble mHTT in the R6/2 mouse.
SIRT2 has been shown to deacetylate tubulin in vitro and in cell
culture experiments [15]. Given the dramatic changes in tubulin
acetylation in the brains of Hdac6KO mice [33], we were surprised
to find no difference in the levels of acetylated tubulin between
brains of Sirt2KO mice and those of wild type mice. It is possible
that SIRT2 is not a bona fide tubulin deacetylase in vivo. Consistent
with this, previous studies could not detect changes in the levels of
acetylated tubulin in mouse embryonic fibroblasts derived from
Sirt2KO mice [41]. Also, double mutant Hdac6KOxSirt2KO mice
are viable and do not display any overt phenotypes up to 4 weeks
of age, arguing for non-redundant roles for HDAC6 and SIRT2
(unpublished observations). Therefore, it is possible that HDAC6,
and not SIRT2, is the major tubulin deacetylase in the brain and
that previous reports suggesting that SIRT2 is a tubulin
deacetylase do not translate to the mammalian system.
Although cytoplasmic in nature, SIRT2 has been shown to
regulate cell cycle progression through deacetylation of H4K16
[17]. Interestingly, we found no changes in the levels of acetylated
H4K16 in brain and liver tissue from Sirt2KO mice. This could
indicate that SIRT2 is only important for cell cycle regulation
under specific conditions, as has been suggested by some, but not
all, previous studies [17,42–44]. Equally, in addition to its role in
cell cycle progression, acetylation of H4K16 has been reported to
be important for cellular processes such as maintenance of active
chromatin for transcription or DNA repair [45]. Given the
fundamental importance of these pathways, it is possible that
compensatory mechanisms to maintain proper H4K16 acetylation
levels exist and could be responsible for the inability to detect
differences in H4K16 acetylation between wild type and Sirt2KO
mice.
A partial rescue of toxicity after genetic knock-down or
pharmacological inhibition of SIRT2 has been observed in D.
melanogaster models of HD and Parkinson’s disease (PD) [22,23,46].
However, the question of whether SIRT2 inhibition affects
behaviour in the context of a mammalian model of HD had not
been previously addressed. The thorough phenotypic character-
Figure 6. Expression of cholesterogenic enzymes at 15 week of age. The Taqman qPCR assay was used to measure the mRNA expression of
the cholesterogenic enzymes in the cortex of 15 week old wild type (WT), Sirt2HET (HET), Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/
2 (R6/2 KO) mice. Values were normalised to the housekeeping genes Atp5b and Canx and expressed as fold change of WT 6 SEM. n$7/genotype.
doi:10.1371/journal.pone.0034805.g006
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depletion did not modulate rotarod performance, grip strength or
spontaneous exploratory activity and had no effect on the brain
weight in WT or in R6/2 mice. Interestingly, reduction and
depletion of SIRT2 caused a significant increase in body weight
that was observed in both WT and R6/2 mice, indicating that this
effect is independent of disease progression. It is possible that the
increased body weight results from the fact that SIRT2 is
important for the inhibition of adipogenesis and could also be
involved in maintaining cellular ATP levels [20,47,48]. Decreased
Figure 7. Expression of cholesterogenic enzymes in WT and R6/2 mice after an acute dose of [S]-35. (A) Structure of [S]-35. (B) Amount
of [S]-35 present in brain samples from mice dosed with vehicle, 1 mg/kg or 3 mg/kg as analysed by LC/MS/MS. No compound was detected in mice
dosed with vehicle alone. n$8/genotype/dose/time point. Black line denotes the SIRT2 IC50 concentration of 560 nM for [S]-35 as determined in in
vitro assays. (C–D) Expression of cholesterogenic enzymes in the cortex of 12 week old wild type (WT) and R6/2 mice (C) 4 h and (D) 8 h after an
acute dose of the [S]-35 SIRT1/SIRT2 inhibitor or vehicle. Values were normalised to the housekeeping genes Atp5b and Canx and expressed as fold
change of WT Vehicle 6 SEM. n$7/genotype/treatment group.
doi:10.1371/journal.pone.0034805.g007
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of the AMPK pathway, which in turn has been shown to affect
multiple downstream events, including hypothalamic inhibition of
POMC, activation of NPY/AgRP and an increase in food intake
[49–51]. Further investigation will undoubtedly reveal which
stages of metabolic control require SIRT2 for adequate weight
maintenance.
The lack of an effect of SIRT2 loss on aggregate load or the
levels of soluble mHTT was very interesting. The pharmacological
inhibition of SIRT2 was found to reduce mHTT inclusion
number in primary striatal neurons, but over-expression of a
catalytically dead SIRT2, had little effect on mHTT inclusion
number in the same model [23]. Additionally, SIRT2 knock-down
rescued a-synuclein mediated toxicity in human neuroglioma cells
but whilst SIRT2 inhibition led to a decrease in the number of
inclusions, it caused an increase in inclusions size in the same
model of PD [46]. No changes in inclusion size were observed
when the same SIRT2 inhibitors were used on primary striatal
HD neurons [23]. In contrast, though not a specific SIRT2
inhibitor, NAM treatment had no effect on inclusion number in
R6/1 mice [13]. Consideration of the previously published
findings together with the data obtained in this study suggests
that not only could mechanisms of aggregate formation be quite
different for a-synuclein and mHTT but also that mHTT
aggregate formation and handling is dependent on the cellular
and organismal context. Our findings indicate that SIRT2
inhibition would be unlikely to affect aggregate load or the levels
of soluble mHTT in HD.
A role for SIRT2 in the modulation of cholesterol content was
proposed after acute inhibition of SIRT2 ameliorated mHTT
toxicity in worm, fly and cell culture HD models [23]. This effect
was attributed to SIRT2 inhibition decreasing cholesterol synthesis
via the cytoplasmic retention of SREBP-2 [23]. Surprisingly, the
expression of seven enzymes of the cholesterol biosynthesis
pathway was found to be unaltered in Sirt2KO mice. Equally,
reduction and depletion of SIRT2 did not affect the expression of
cholesterol biosynthesis enzymes at late stage disease in R6/2
mice. These data indicate that SIRT2 does not play a role in
cholesterol synthesis in the mouse. As previous work linking
SIRT2 to cholesterol synthesis was performed with inhibitors, the
observed effects on the cholesterol pathway could be the result of
off-target effects. Although changes in the expression of Fdft1,
Hgmcs1 and Hmgcr were also detected after over-expression of a
catalytically dead SIRT2, viral transduction and over-expression
of a protein can also evoke compensatory mechanisms or aberrant
interactions within cells [23]. On the other hand, it was possible
that the lack of changes in the expression of cholesterol
biosynthesis enzymes after SIRT2 genetic depletion could be a
result of compensatory mechanisms. However, our demonstration
that acute SIRT2 inhibition does not affect the expression levels of
cholesterol biosynthesis enzymes, verified that confounding
compensatory effects were unlikely to have occurred. Our data
indicate that SIRT2 does not play a role in cholesterol biosynthesis
and that the previously observed findings are either a result of off-
target effects of the inhibitors used or due to differences between
primary cell culture and mouse models.
Previously published reports on the role of SIRT2 as a modifier
of neurodegenerative disease clearly provided a rationale for
conducting a phenotypic study in a mouse model of HD. Our
finding that depletion of SIRT2 does not modify HD progression
in R6/2 mice was surprising and the relevance of this model could
be questioned. Although R6/2 mice express an N-terminal
fragment of mHTT and thus lack the context of full length
mutant protein, the possible involvement of SIRT2 in cholesterol
biosynthesis originated from studies in cells expressing an N-
terminal fragment of mHTT [23]. This indicates that the R6/2
mouse is an ideal system to extend the cellular work and study
SIRT2 depletion or inhibition in the context of a mammalian
brain. In addition, although knock-in models of HD are genetically
precise, the striking similarity between the phenotypes that develop
in the R6/2 and HdhQ150 knock-in models suggests that the rate
limiting step in disease onset and progression in these mice is likely
to be the formation of an N-terminal mHTT fragment [25,52]. A
such, it is highly unlikely that the genetic depletion of SIRT2
would modify HdhQ150 knock-in phenotypes, and as the time and
resources required to perform these experiments are considerable,
priorities should be directed toward the validation of more
convincing therapeutic targets.
Given the devastating nature of HD and the lack of disease
modifying treatments, considerable effort has been invested in the
search for, and validation of, therapeutic strategies. Pan HDAC
and sirtuin inhibitors such as SAHA and NAM have been shown
to ameliorate disease phenotype in HD mice but can be associated
with significant toxic effects. In order to divorce the toxic and
beneficial effects of HDAC inhibition, considerable efforts have
been made to determine which HDAC(s) and sirtuin(s) are key
modifiers of disease progression. Genetic knock-down or knock-
out of HDAC3, 5, 6, 7 and 9 has shown no benefit in R6/2 mice
(unpublished data and [33,53,54]) whereas genetic knock-down of
HDAC4 resulted in a marked improvement in R6/2 behavioural
and molecular phenotypes (unpublished data). Similarly, whilst we
have shown that a reduction in SIRT2 does not modify HD-
related phenotypes in an HD mouse model, overexpression of
SIRT1 has recently been shown to have beneficial consequences
[14,55]. This study demonstrates that SIRT2 does not modify
disease progression in R6/2 mice and should not be prioritised as
a therapeutic target for HD.
Materials and Methods
Ethics statement
All experimental procedures performed on mice were approved
by the King’s College London Ethical Review Process Committee
and carried out under Home Office License 70/6545.
Mouse husbandry
Hemizygous R6/2 mice were maintained by backcrossing R6/2
males to CBAxC57BL/6 F1 (CBF) females (B6CBAF1/OlaHsd,
Harlan Olac, UK). Sirt2 knock-out (Sirt2KO) mice were on
C57BL/6/129Ola background and were backcrossed to CBF
three times.
At 4 weeks of age, mice were weaned into cages of 5 or 6
animals. Each cage contained at least one representative of each
genotype when available. Animals were housed under 12 h light/
12 h dark cycle, with unlimited access to water and chow (Special
Diet Services, Witham, UK). Cages were environmentally
enriched as described [56]. R6/2 mice and all mice in phenotypic
assessment trials were always given mash food consisting of
powdered chow mixed with water from 12 weeks of age until
sacrificed.
Mouse genotyping and repeat sizing
All mice were genotyped by PCR of tail-tip DNA. R6/2 mice
were genotyped and repeat sizes were determined as described
previously [26]. Sirt2 mice were genotyped with all 3 primers
(Table S2) at 5 mM final concentration in a 15 mL multiplex
reaction also containing 1 mL 100 ng/mL DNA, 1.5 mL2m M
dNTP, 3 mL Phire reaction buffer (56) and 0.2 mL Phire Hot Start
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follows: 98uC for 30 s, (98uC for 20 s, 63uC for 20 s and 72uC for
30 min)635, followed by 1 min at 72uC.
Mouse phenotypic assessment
All tests were performed blind to the genotype. Mice were
weighed weekly to the nearest 0.01 g. Brains were harvested with
optic bulbs intact and weighed to the nearest 0.001 g immediately
after cervical dislocation. Forelimb grip strength was assessed as
described [56] at 4 weeks of age and then bi-weekly from 7 weeks
of age. Motor coordination was assessed using an Ugo Basile 7650
rotarod, modified to accelerate from 4 to 44 rpm over 300 s, as
described [56]. Spontaneous exploratory motor activity was
measured bi-weekly from 5 to 13 weeks of age as described
previously [36]. Mice were tested at the same time of day, with
male mice always tested before female mice and cages cleaned
thoroughly in between the two sexes. Data were analysed for
activity (total number of beam brakes in the lower level), mobility
(at least two consecutive beam breaks in the lower level), rearing
(beam break in upper level) and centre rearing (beam breaks in
upper level away from the cage walls).
Sirt2 KO mutation sequencing
Tail-tip DNA from Sirt2KO mice and WT littermates was used
for PCR with Qiagen Type-it Mutation Detection kit using 200 ng
DNA in a 50 mL reaction containing 25 mL2 6Master mix, 5 mL
Sirt2 forward primer, 5 mL Sirt2 reverse KO primer and 10 mLQ
solution, with cycling conditions of: 95uC for 10 min, (95uC for
30 s, 65uC for 90 s, 72uC for 60 s)630 and 68uC for 10 min. The
PCR product was purified with the Qiaquick Gel Extraction kit
according to manufacturer’s instructions and cloned into TOP10
bacteria using the Invitrogen TOPO TA cloning kit according to
manufacturer’s instructions. Plasmid DNA was isolated with
Qiaprep Spin Miniprep Kit according to manufacturer’s instruc-
tions and eluted in ultra-pure water. Sequencing reactions were
carried out in a 6.25 mL volume containing 200–500 ng DNA,
0.25 mL BigDye v3.1 (Applied Biosystems), 1.25 mL sequencing
buffer, 0.25 mL primer (80 ng/mL) under cycling conditions of:
96uC for 2 min, (96uC for 30 s, 50uC for 20 s, 60uC for
1 min)630. PCR products for sequencing were precipitated with
26 mL sequencing precipitation solution (120 mM C2H3O2Na in
95% absolute ethanol), incubated for 10 min at room temperature
and centrifuged at 3,0006 g for 20 min. The supernatant was
removed, the pellet washed with 100 mL 70% ethanol, centrifuged
at 3,0006g for 20 min, cleared of supernatant and re-suspended
in 10 mL Hidi-formamide (Applied Biosystems). The sample was
then denatured at 96uC for 2 min and analysed with an ABI3730
sequencer. Sequence traces were analysed with the ABI Sequenc-
ing Analysis and Vector NTI programmes. The primer sequences
used are given in Table S2.
Tissue preparation
Dissected brain regions, whole brains or peripheral tissues were
snap frozen in liquid nitrogen and stored at 280uC until use.
Nuclear/cytoplasmic fractionation
Whole brains were homogenised in 2 volumes of ice cold
sucrose buffer 1 (575 mM sucrose, 25 mM KCl, 50 mM
triethanolamine hydrochloride pH 7.5, 5 mM MgCl2,1 m M
DTT, 1 mM PMSF, 5 mM TSA, 10 mM nicotinamide, Complete
protease inhibitor cocktail (Roche)) with 10 gentle pestle strokes in
a Dounce homogeniser. The homogenates were centrifuged at
5006g for 15 min at 4uC. The supernatant (cytoplasmic fraction)
was removed and stored at 280uC. The pellet was re-suspended in
1 mL of ice cold sucrose buffer 1 with an additional 10 gentle
pestle strokes in the Dounce homogeniser. Two volumes of ice
cold sucrose buffer 2 (2.3 M sucrose, 2.5 mM KCl, 50 mM
triethanolamine hydrochloride pH 7.5, 2.5 mM MgCl2,1m M
DTT, 1 mM PMSF, 5 mM TSA, 10 mM nicotinamide, Complete
protease inhibitor cocktail (Roche)) were added to the homogenate
and the solution was mixed until uniform. Ultracentrifuge tubes
were layered with a 0.5 mL cushion of sucrose buffer 2 and the
homogenate was gently layered on top. The tubes were
appropriately balanced and spun in pre-cooled SW41 rotor tubes
at 124,0006g for 1 h at 4uC. Subsequently, the supernatant was
removed and the pellet re-suspended in 0.5 mL sucrose buffer 1,
transferred to fresh 1.5 mL tubes and spun at 8006g for 15 min at
4uC. The supernatant was removed and the pellet was re-
suspended in 0.5 mL buffer 1, spun at 8006g for 15 min at 4uC
twice more before being re-suspended in 50 mL of buffer 1. The
nuclear fraction was sonicated on ice for 10 s at 80 Hz. The
protein concentration of both fractions was determined with the
BCA assay (Thermo Scientific) for each sample.
Acid extraction of histone proteins
Tissues were homogenised in 1 volume of acid extraction buffer
(5% (v/v) Triton X-100, 3 mM DTT, 1 mM Orthovanadate,
5 mM NaF, 1 mM PMSF, 5 mM TSA, 10 mM nicotinamide,
Complete protease inhibitor cocktail) using a polytron homoge-
nising probe and centrifuged at 8006 g for 8 min at 4uC. The
supernatant was removed and the pellet washed twice by re-
suspending in acid extraction buffer, and centrifuging at 8006 g
for 8 min at 4uC. The pellet was then re-suspended in 80 mLo f
0.2 M HCl and incubated for 3 h at 4uC with constant shaking at
800 rpm. Samples were then centrifuged at 8006 g for 8 min at
4uC, the supernatant collected, neutralised with 16 mLo f1M
NaOH, and the protein concentration determined for each sample
with the BCA kit.
Tissue preparation for SDS PAGE and Western blotting
Unless nuclear/cytoplasmic fractionation, acid extraction or
Seprion ELISA were performed, tissue was homogenised in 1
volume of ice cold RIPA buffer (150 mM NaCl, 1% (v/v) NP-40,
0.5% (w/v) Na deoxycholate, 0.1% (w/v) SDS, 50 mM Tris-HCl
pH 8.0, 1 mM 2-mercaptoethanol, 10 mM DTT, 1 mM PMSF,
5 mM TSA, 10 mM nicotinamide, Complete protease inhibitor
cocktail) or TX buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl,
2 mM EDTA, 1% (v/v) Triton - X100, 1 mM PMSF, 5 mM TSA,
10 mM nicotinamide, Complete protease inhibitor cocktail) (TX
was used for tubulin acetylation and RIPA buffer for all other
experiments) with a polytron homogenising probe. Homogenates
were sonicated on ice for 10 s at 80 Hz. Lysates were cleared by
centrifugation at 16,2006 g for 15 min at 4uC. Protein
concentration was measured by BCA assay for each sample.
SDS PAGE and Western blotting
Samples were diluted with 26Laemmli buffer (125 mM Tris–
HCl pH 6.8, 20% glycerol, 4% SDS, 0.01% (w/v) bromophenol
blue) and denatured for 5 min at 95uC. Equal amounts of protein
were loaded onto an SDS polyacrylamide gel alongside a size
reference. Proteins were transferred onto nitrocellulose membrane
at 120 V for 90 min by a submerged transfer apparatus in transfer
buffer. Membranes were blocked in 5% non-fat dried milk in PBS
for at least 1 h. Primary antibodies were applied in 0.02% PBS-
Tween 20 (PBST) for 20 min (acetylated a-tubulin; a-tubulin;
actin; H3 and H4), 1 hour (S829; SIRT2 (S8847) at room
temperature or overnight (SIRT2 (sc-20966); SIRT1; SREBP-2;
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Blots were washed three times for 5 min in 0.2% PBST and
incubated with appropriate HRP coupled secondary antibody. For
signal detection the enhanced chemi-luminescence (ECL) detec-
tion system, hyperfilms and Xenograph developer were used
according to the manufacturers’ instructions. Signals were
quantified using GS-800 densitometer.
Antibodies and the dilutions at which they were used are
presented in Table S3. The antibodies MW1 [57], MW8 [57], 2B7
[58] are not commercially available and were kind gifts as noted in
Table S3. The S829 antibody was developed in house by the
Scottish Antibody Production Unit using the same epitope as that
for S830 [59].
Coomassie staining of polyacrylamide gels
Polyacrylamide gels were stained with Coomassie solution
(0.25% (w/v) Brilliant blue R-250, 50% (v/v) methanol, 10% (v/v)
acetic acid) for 30 min with gentle agitation. Gels were then
washed several times in ddH2O and three times for 10 min in de-
staining solution (16.5% (v/v) methanol, 0.5% (v/v) acetic acid).
Gels were dried in a vacuum gel drier.
Seprion ELISA
For SDS-insoluble aggregate detection, 2.5% (w/v) lysates were
prepared by homogenising tissue in ice cold RIPA buffer.
Aggregate load was measured as previously described [26].
TR-FRET
Time Resolved – Fo ¨rster Resonance Energy Transfer (TR-
FRET) experiments were performed as previously described [58].
Mesoscale electrochemiluminescence detection of
soluble and aggregated mutant huntingtin
384-well high bind MesoScale Discovery L21XB plates were
coated at 4uC over night with 12 ml/well of 30 mg/ml 2B7-
antibody for soluble mutant huntingtin detection or 10 mg/ml
MW8-antibody for aggregated mutant huntingtin detection. Wells
were washed with wash buffer (20 mM Tris, 0.9% NaCl, 0.2%
Tween-20) and blocked with 35 ml Starting Block T20 (#37539
Thermo) per well. After washing, 10 ml tissue homogenate was
applied. Plates were incubated for 1 h at room temperature while
shaking at 450 rpm. Wells were washed and 10 ml/well detection
antibody (10 mg/ml MW1-Sulfo-tag diluted 1:10 in Starting Block
T20 for soluble, 10 mg/ml MW8-Sulfo-tag diluted 1:10 in Starting
Block T20 for aggregated mutant huntingtin) were added. Plates
were incubated for 1 h at room temperature while shaking at
450 rpm. After final washing steps, 26 R92TC-2 MSD Read
Buffer was added and plates were analyzed with a MSD SECTOR
Imager 6000 reader.
Gene expression analysis
RNA extraction, cDNA synthesis, Taqman RT-qPCR and DCt
analyses were performed as previously described [60]. House-
keeping genes were selected appropriate to the tissue examined.
Primers and probe mixes for housekeeping genes, Sirt4, Sirt6 and
cholesterol pathway genes were purchased from Primer Design.
Primers for analysis of expression of Hdac1-11, Sirt1-3, Sirt5 and
Sirt7 are listed in Table S2.
Dosing of mice with [S]-35
The [S]-35 SIRT1/SIRT2 inhibitor was synthesized at
Cychem. [S]-35 was formulated in the vehicle solution (30%
PEG-400, 20% Solutol HS15, 0.5% Lutrol F68 – all from BASF)
immediately prior to dosing. 12 week old WT and R6/2 mice
(N$9/genotype) were weighed and given one acute dose of either
vehicle, or formulated [S]-35 at 1 mg/kg or 3 mg/kg by oral
gavage and dissected either 4 or 8 hours later. Each treatment
group contained mice matched for age, sex and CAG repeat
number.
Measurement of brain and plasma levels of [S]-35
Blood was collected into EDTA tubes after cardiac puncture
and stored on ice before centrifugation for 10 min at 4uCa t
16 1006 g. The plasma was removed and frozen at 220uC.
Brains were removed, rinsed with saline to remove blood,
weighed, and immediately frozen at 220uC. Analysis of the
pharmacokinetic properties of [S]-35 was performed in 6–7 week
old male C57BL/6 mice at Pharmadex and the levels of [S]-35 in
the brains of WT and R6/2 mice 4 h and 8 h post dosing was
performed at BioFocus.
Sample preparation for bioanalysis. Brain tissue was
homogenized in acetonitrile:water (3:1, v/v) using an Precellys
tissue homogenizer; the tissue-to-solvent ratio was of 1:3 (w/v).
Aliquots (25 mL of plasma or 100 mL tissue homogenate) of study
samples, and corresponding controls were dispensed into 96-well
plates. One hundred (100) mL of solvent containing internal
standard (0.1% formic acid in acetonitrile with 200 ng/mL
diclofenac as the internal standard) were added to all samples
except matrix double blanks and solvent blanks. Acetonitrile:water
(75:25 v/v) without internal standard (100 mL) was added to
matrix double blanks. Samples were vortexed and centrifuged for
5 min, 100 mL of the supernatants were transferred to a new plate,
diluted with 100 mL of acetonitrile:Milli-Q water (75:25 v/v) and
submitted to LC-MS/MS analysis.
Bioanalytical Method. Concentrations in mouse plasma and
brain were determined using LC-MS/MS assays. UPLC reverse
phase separation was performed on a Waters Acquity UPLC
chromatography system using a Waters Acquity UPLC BEH C18
column (5062.1 mm, 1.7 mm); the column temperature was
maintained at 40uC. The mobile phase consisted of acetonitrile
containing 0.01% v/v formic acid (B) and milliQ water containing
0.01% v/v formic acid (A). A gradient elution program (flow rate
0.6 mL/min) was used with initial conditions of 5% B. These
conditions were maintained for 0.2 min, followed by a linear
increase to 95% B over 1 min, maintained at 95% B for 0.6 min
before returning to initial conditions; the total run time was 2 min.
An injection volume of 5 mL was used. The entire LC eluent was
directly introduced to an electrospray (ESI) source for LC/MS/
MS analysis on a Waters TQMS Xevo triple quadrupole mass
spectrometer with a source temperature of 150uC and a
desolvation temperature of 500uC. Positive ion mode of ESI was
used for the analysis. The mass spectrometer ion optics were set in
the multiple reaction monitoring (MRM) mode, and the following
transitions were monitored: 263.98.218.92 for [S]-35 and
296.05.214.14 for diclofenac (the internal standard). The data
was processed using QuanLynx software from Waters. Using this
method, the retention time of [S]-35 and the IS were 1.18 and
1.28 min, respectively. The lower limit of assay quantitation
(LLOQ) for [S]-35 was 3.8 nM for both plasma and brain.
Statistical Analysis
Statistical analysis was performed with SPSS (three-way
ANOVA, repeated measures ANOVA General Linear Model
with Greenhouse-Geisser correction for non-sphericity) or Micro-
soft Excel (Student’s t-test) software. For mouse phenotypic
assessment, weight, rotarod and grip strength were analysed with
repeated measures ANOVA and at each time point with three-
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Activity was analysed with repeated measures ANOVA at each
time point separately. For western blotting, ELISA, TR-FRET
and qPCR, group means were compared by Student’s t-test, two
or three-way ANOVA.
Supporting Information
Figure S1 Sequence of the Sirt2 knock-out mutation.
Genomic sequence of the mouse Sirt2 gene with the position and
sequence of the mutation as present in the Sirt2KO mice. The
inserted sequence (mutation) is highlighted in yellow. The mouse
Sirt2 genomic sequence was obtained from NCBI under accession
number: NC_000073.5.
(DOCX)
Figure S2 Expression of Hdacs 1-11, Sirt1-7 and SIRT1.
(A–B) Taqman qPCR assays measuring the mRNA expression of
all known deacetylases in the cortex of 4 week old wild type (WT),
Sirt2HET (HET) and Sirt2KO (KO) mice. Expression was
normalised to the housekeeping genes Atp5b and Canx and
expressed as fold change of WT 6 SEM. n$6/genotype. (C)
Representative western blot probed with SIRT1 antibody showing
SIRT1 expression between wild type (WT) and Sirt2KO (KO)
brain lysates extracted from cortices of 9 week old mice in RIPA
buffer. * denotes a non-specific band. Tubulin (Tub) was used as
loading control. n$3/genotype.
(TIF)
Figure S3 SIRT2 expression is comparable between 4
and 15 weeks and not affected by HD progression. (A)
Representative western blot showing SIRT2 expression in
different brain regions at 4 and 15 weeks of age in wild type
mice. The signal for SIRT2 was normalised to total protein loaded
(Coomasie stain) and expressed as fold change of rest of brain (Rb)
(containing all regions except cortex (Cx), striatum (S), hippocam-
pus (H), cerebellum (Cb) and brain stem (BS)) 6 SEM. n=4/brain
region/time point. (B) Taqman qPCR assay measuring levels of
Sirt2 mRNA between wild type (WT) and R6/2 mice at 4 and 15
weeks of age in cortex, striatum and cerebellum. Expression was
normalised to the housekeeping genes Atp5b and Canx, and
expressed as fold change of WT 6 SEM. n$6/genotype.
(TIF)
Figure S4 Activity and mobility. Activity (single lower beam
break) and mobility (consecutive lower beam breaks) were
recorded for wild type (WT), Sirt2HET (HET), Sirt2KO (KO),
R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2
KO) mice over the course of 30 min at 5, 7, 9, 11, and 13 weeks of
age. Activity parameters measurements were visualised by plotting
5 min moving averages.
(TIF)
Figure S5 Rearing and centre rearing. Rearing (upper
beam break) and centre rearing (unsupported upper beam break)
were recorded for wild type (WT), Sirt2HET (HET), Sirt2KO
(KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2
(R6/2 KO) mice over the course of 30 min at 5, 7, 9, 11, and 13
weeks of age. Activity parameters measurements were visualised by
plotting 5 min moving averages.
(TIF)
Figure S6 Soluble and aggregated mHTT in the cortex,
hippocampus, brain stem and cerebellum measured by
MSD. Levels of soluble (upper panels) and aggregated (lower
panels) mHTT as measured by Mesoscale Discovery (MSD) in (A)
cortex, (B) hippocampus, (C) brain stem, and (D) cerebellum at 4,
9 and 15 weeks of age in R6/2, Sirt2HETxR6/2 (R6/2 HET) and
Sirt2KOxR6/2 (R6/2 KO) mice. Soluble mHTT was measured
with 2B7-MW1 and aggregated mHTT with MW8-MW8
antibody combinations. The signal for each tissue was expressed
as fold change of R6/2 at 4 weeks of age. A signal was not
observed above background for mice without the R6/2 transgene.
n$4/genotype/tissue/time point (except for R6/2 KO at 4 weeks
where n=3). Error bars represent SEM. *p#0.05, **p#0.01 (to
the R6/2 at the respective time point).
(TIF)
Figure S7 Pharmacokinetic properties of [S]-35 in
mouse brain after acute dosing. Plasma and brain levels of
[S]-35 following intravenous (IV), or oral gavage (PO) adminis-
tration. Male, 6–7 weeks old C57BL/6 mice were dosed with
5 mg/kg (IV) or 10 mg/kg (PO) of [S]-35 and plasma and brains
were harvested at various timepoints after compound administra-
tion. Concentration of [S]-35 in the analyte was measured by LC/
MS/MS. n=4 per timepoint, mean 6 standard deviation shown.
(TIF)
Table S1 Genetic depletion of SIRT2 does not modify
R6/2 exploratory behaviour. The p values displayed in Table
S1 indicate whether the activity measures: activity, mobility,
rearing and centre rearing are significantly influenced by R6/2
genotype, Sirt2 genotype, Sex and the duration of the 30 min test
(Time) at 5, 7, 9, 11 and 13 weeks of age. Significant p-values are
highlighted in blue for p,0.05, orange for p,0.01 and pink for
p,0.001.
(DOCX)
Table S2 Summary of primer and probe sequences
designed in-house.
(DOCX)
Table S3 Summary of all antibodies used in this study.
(DOCX)
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